Palliative care should be introduced as early as possible, even as early as diagnosis, so patients hear about it early and not during a late stage of their disease when they might need hospice, Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing, said at the National Comprehensive Cancer Network Annual Meeting.
Palliative care should be introduced as early as possible, even as early as diagnosis, so patients hear about it early and not during a late stage of their disease when they might need hospice, Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing, said at the National Comprehensive Cancer Network Annual Meeting.
Transcript (slightly modified)
How early in the cancer care process should palliative care be introduced?
As early as possible. We talked a lot today about some of the stigma involved with palliative care terms, such as hospice, and the feeling is among providers that the earliest it's introduced, even at diagnosis, and palliative care is introduced as a way to provide symptom management and psychosocial supportive care to the patient throughout the trajectory. And that way the patient hears about it early on and it's not thrown at the patient late in their disease process when, perhaps, their condition has deteriorated and they need to seek out specialty services, like hospice.
So, I'm a big proponent of having the discussion early on, and that way the patient can take advantage of the services as well. Palliative care is not just hospice—hospice is just one form of palliative care. Palliative care really, if it's done right, it's done across providers, by a multi-disciplinary team that's focused on the entire patient, and not just their disease. So it's all about "how do we maximize quality of life throughout the cancer trajectory?"
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More